Effect of selective and non-selective β-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure
| Autor: | Matej Podbregar, Mitja Lainscak, Lidija Gobec, Dragan Kovačić, Matej Marinšek |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Blood Glucose
Leptin Male medicine.medical_specialty medicine.medical_treatment Adrenergic beta-Antagonists Carbazoles Propanolamines Insulin resistance Internal medicine medicine Bisoprolol Homeostasis Humans Insulin Resistin cardiovascular diseases Carvedilol Aged Heart Failure business.industry Body Weight General Medicine Middle Aged medicine.disease Endocrinology Heart failure Chronic Disease Cardiology Female Insulin Resistance Cardiology and Cardiovascular Medicine business hormones hormone substitutes and hormone antagonists medicine.drug |
| Zdroj: | Clinical Research in Cardiology. 97:24-31 |
| ISSN: | 1861-0692 1861-0684 |
| DOI: | 10.1007/s00392-007-0571-3 |
| Popis: | Chronic heart failure (CHF) is characterized by increased insulin resistance and hyperleptinaemia. We aimed to study effects of selective and non-selective beta-blockers on body weight, insulin resistance, plasma concentrations of leptin and resistin in patients with CHF.Twenty-six non-cachectic beta-blocker-naive patients with CHF were randomized and treated with either carvedilol or bisoprolol. Body weight, plasma concentrations of leptin, resistin, fasting glucose and insulin were measured at baseline and after 6 months of therapy. Insulin resistance was estimated by homeostasis model assessment- estimated insulin resistance (HOMA-IR).Body weight increased significantly in the carvedilol group (mean change + 2.30 kg, p = 0.023) while it did not change in the bisoprolol group (mean change -0.30 kg, p = 0.623) (ns between groups). Plasma leptin concentration increased only in the carvedilol group (mean change + 4.20 ng/ml, p = 0.019) (ns between groups). Fasting glucose and resistin remained unchanged in both groups. After 6 months, mean plasma insulin concentration changed significantly differently (p = 0.015) in the bisoprolol (mean change +3.1 microU/ml) compared to the carvedilol group (mean change -6.3 microU/ml) and HOMA-IR was consequently higher in the bisoprolol compared to the carvedilol group (5.2 +/- 4.2 vs 2.8 +/- 1.6, p = 0.046).This study found different metabolic effects of carvedilol and bisoprolol in non-cachectic patients with CHF. With unchanged fasting plasma glucose concentration after 6 months of treatment, carvedilol significantly decreased plasma insulin concentration and insulin resistance compared to bisoprolol. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink